Peter Campochiaro

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Treatment of macular edema due to retinal vein occlusions
    Roomasa Channa
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Ophthalmol 5:705-13. 2011
  2. doi request reprint Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study
    Peter A Campochiaro
    The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland Electronic address
    Ophthalmology 121:209-19. 2014
  3. pmc Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate
    Mohamed A Ibrahim
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    BMC Pharmacol Toxicol 14:7. 2013
  4. doi request reprint Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants
    Peter A Campochiaro
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 120:583-7. 2013
  5. doi request reprint Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 120:795-802. 2013
  6. doi request reprint Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study
    Peter A Campochiaro
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Am J Ophthalmol 155:697-704, 704.e1-2. 2013
  7. pmc Ocular neovascularization
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    J Mol Med (Berl) 91:311-21. 2013
  8. doi request reprint Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema
    Peter A Campochiaro
    Wilmer Eye Institute, Baltimore, Maryland, USA
    Ophthalmology 119:2125-32. 2012
  9. doi request reprint Anti-vascular endothelial growth factor treatment for retinal vein occlusions
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ophthalmologica 227:30-5. 2012
  10. doi request reprint Gene transfer for ocular neovascularization and macular edema
    P A Campochiaro
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    Gene Ther 19:121-6. 2012

Research Grants

  1. FUNCTIONS OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 1999
  2. Targeting survival factors for ocular neovascularization
    Peter Campochiaro; Fiscal Year: 2009
  3. Oxidative damage and cone cell death in RP
    Peter Campochiaro; Fiscal Year: 2009
  4. FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 2004
  5. Molecular Signals Involved in Ocular Neovascularization
    Peter Campochiaro; Fiscal Year: 2004
  6. Molecular Signals Involved in Ocular Neovascularization
    Peter Campochiaro; Fiscal Year: 2005
  7. Oxidative damage and cone cell death in RP
    Peter Campochiaro; Fiscal Year: 2007
  8. Targeting survival factors for ocular neovascularization
    Peter Campochiaro; Fiscal Year: 2007
  9. Oxidative damage and cone cell death in RP
    Peter Campochiaro; Fiscal Year: 2009
  10. Oxidative damage and cone cell death in RP
    Peter A Campochiaro; Fiscal Year: 2010

Detail Information

Publications95

  1. pmc Treatment of macular edema due to retinal vein occlusions
    Roomasa Channa
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Ophthalmol 5:705-13. 2011
    ..Standard care for patients with RVO has changed and will continue to evolve as results with other new agents are revealed...
  2. doi request reprint Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study
    Peter A Campochiaro
    The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland Electronic address
    Ophthalmology 121:209-19. 2014
    ..To determine long-term outcomes of patients with ranibizumab-treated retinal vein occlusion (RVO)...
  3. pmc Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate
    Mohamed A Ibrahim
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    BMC Pharmacol Toxicol 14:7. 2013
    ..This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD)...
  4. doi request reprint Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants
    Peter A Campochiaro
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 120:583-7. 2013
    ..To compare aqueous levels of fluocinolone acetonide (FAc) after administration of FAc inserts or FAc implants (Retisert; Bausch & Lomb, Rochester, NY)...
  5. doi request reprint Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 120:795-802. 2013
    ..Many patients also show areas of complete closure of retinal vessels (retinal nonperfusion [RNP]) that increase over time. The objective was to assess the effect of blocking VEGF on progression of RNP...
  6. doi request reprint Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study
    Peter A Campochiaro
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Am J Ophthalmol 155:697-704, 704.e1-2. 2013
    ..DARPins are a novel class of proteins selected for specific, high-affinity binding to a target protein...
  7. pmc Ocular neovascularization
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    J Mol Med (Berl) 91:311-21. 2013
    ..While substantial progress has been made, the future looks even brighter for patients with retinal and choroidal vascular diseases...
  8. doi request reprint Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema
    Peter A Campochiaro
    Wilmer Eye Institute, Baltimore, Maryland, USA
    Ophthalmology 119:2125-32. 2012
    ..To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME)...
  9. doi request reprint Anti-vascular endothelial growth factor treatment for retinal vein occlusions
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ophthalmologica 227:30-5. 2012
    ..The role of adjunctive treatments is yet to be defined, but it is clear that VEGF antagonists provide excellent first-line treatment that has dramatically improved visual outcomes in patients with RVO...
  10. doi request reprint Gene transfer for ocular neovascularization and macular edema
    P A Campochiaro
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    Gene Ther 19:121-6. 2012
    ....
  11. pmc Gene transfer for neovascular age-related macular degeneration
    Peter A Campochiaro
    Department of Ophthalmology and Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Gene Ther 22:523-9. 2011
    ..Many important questions remain, but the rationale and preliminary data are compelling. The results of two ongoing clinical trials may answer several of the questions and help direct future research...
  12. doi request reprint Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins School of Medicine, Baltimore, MD 21287 9277, USA
    Ophthalmology 118:2041-9. 2011
    ..Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO)...
  13. ncbi request reprint Ocular neovascularisation and excessive vascular permeability
    Peter A Campochiaro
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
    Expert Opin Biol Ther 4:1395-402. 2004
    ..Gene transfer provides a useful way to influence these balances. Clinical trials are underway to test whether these mechanisms can be translated into new therapies...
  14. doi request reprint Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes
    Peter A Campochiaro
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 117:2387-2394.e1-5. 2010
    ..To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs)...
  15. doi request reprint Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema
    Peter A Campochiaro
    The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 118:626-635.e2. 2011
    ..To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular edema (DME)...
  16. ncbi request reprint Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study
    Peter A Campochiaro
    The Wilmer Eye Institute, Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 117:1102-1112.e1. 2010
    ..To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema following branch retinal vein occlusion (BRVO)...
  17. ncbi request reprint Targeted pharmacotherapy of retinal diseases with ranibizumab
    Peter A Campochiaro
    The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Drugs Today (Barc) 43:529-37. 2007
    ....
  18. ncbi request reprint Gene therapy for ocular neovascularization
    Peter A Campochiaro
    The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    Curr Gene Ther 7:25-33. 2007
    ..It is likely that additional vectors and transgenes will enter clinical trials in the near future. This report discusses the rationale and experimental evidence regarding several candidate transgenes...
  19. doi request reprint Monitoring ocular drug therapy by analysis of aqueous samples
    Peter A Campochiaro
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 116:2158-64. 2009
    ..To assess the value of sampling aqueous humor for measurement of potential molecular targets and for pharmacokinetic analysis...
  20. ncbi request reprint Molecular targets for retinal vascular diseases
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 210:575-81. 2007
    ..This review summarizes preclinical and clinical trial results obtained with VEGF antagonists and describes evidence supporting the candidacy of other molecules currently being tested or soon to be tested for target status...
  21. pmc Topical mecamylamine for diabetic macular edema
    Peter A Campochiaro
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Am J Ophthalmol 149:839-51.e1. 2010
    ..The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema...
  22. doi request reprint Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert
    Peter A Campochiaro
    The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 117:1393-9.e3. 2010
    ..To compare Iluvien intravitreal inserts that release 0.2 or 0.5 microg/day of fluocinolone acetonide (FA) in patients with diabetic macular edema (DME)...
  23. ncbi request reprint Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial
    Peter A Campochiaro
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Gene Ther 17:167-76. 2006
    ..11 in patients with neovascular AMD should be performed...
  24. ncbi request reprint Ocular versus extraocular neovascularization: mirror images or vague resemblances
    Peter A Campochiaro
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 47:462-74. 2006
  25. ncbi request reprint Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders
    P A Campochiaro
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, MD 21287 9277, USA
    Gene Ther 13:559-62. 2006
    ..Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases...
  26. doi request reprint Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator
    Peter A Campochiaro
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Mol Ther 16:791-9. 2008
    ....
  27. ncbi request reprint Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Invest Ophthalmol Vis Sci 45:922-31. 2004
    ..To evaluate the efficacy and safety of PKC412, an orally administered kinase inhibitor, in subjects with diabetic macular edema...
  28. ncbi request reprint Gene therapy for retinal and choroidal diseases
    Peter A Campochiaro
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    Expert Opin Biol Ther 2:537-44. 2002
    ....
  29. ncbi request reprint Seeing the light: new insights into the molecular pathogenesis of retinal diseases
    Peter A Campochiaro
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 213:348-54. 2007
    ..Initial treatments that provide benefit from frequent intraocular injections are likely to be followed by sustained delivery of drugs and/or prolonged protein delivery by gene transfer. The eye has entered the era of molecular therapy...
  30. ncbi request reprint Retinal and choroidal neovascularization
    P A Campochiaro
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 184:301-10. 2000
    ..This review summarizes recent progress in the field of ocular neovascularization and the prospects that it provides for the development of new treatments...
  31. ncbi request reprint The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration
    P A Campochiaro
    The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    Mol Vis 5:34. 1999
    ..Identification of alterations in gene expression will provide targets for rational design of drug treatment...
  32. doi request reprint Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study
    Quan Dong Nguyen
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 116:2175-81.e1. 2009
    ..To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME)...
  33. ncbi request reprint Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor
    Keisuke Mori
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 43:2428-34. 2002
    ....
  34. ncbi request reprint AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization
    Keisuke Mori
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 43:1994-2000. 2002
    ..The purpose of this study was to determine whether AAV-mediated intraocular gene transfer of pigment epithelium-derived factor (PEDF) inhibits the development of choroidal neovascularization (CNV) in a murine model...
  35. ncbi request reprint Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth
    Elia J Duh
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Maumenee 809, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Invest Ophthalmol Vis Sci 43:821-9. 2002
    ....
  36. doi request reprint Trans-scleral delivery of antiangiogenic proteins
    Anna M Demetriades
    Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    J Ocul Pharmacol Ther 24:70-9. 2008
    ..In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein...
  37. ncbi request reprint Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies
    Keisuke Mori
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
    Invest Ophthalmol Vis Sci 43:1610-5. 2002
    ....
  38. ncbi request reprint Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment
    Kyoichi Takahashi
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, Maryland 21287 9277, USA
    FASEB J 17:896-8. 2003
    ..In patients with diabetic retinopathy, endostatin gene transfer may provide a way to decrease the risk of three causes of visual loss: macular edema, neovascularization, and retinal detachment...
  39. pmc Oxidative stress promotes ocular neovascularization
    Aling Dong
    Departments of Ophthalmology and Neuroscience, Johns Hopkins, University School of Medicine, Baltimore, Maryland, USA
    J Cell Physiol 219:544-52. 2009
    ..J. Cell. Physiol. 219: 544-552, 2009. (c) 2009 Wiley-Liss, Inc...
  40. ncbi request reprint Vascular endothelial growth factor is a critical stimulus for diabetic macular edema
    Quan Dong Nguyen
    The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Am J Ophthalmol 142:961-9. 2006
    ..The role of vascular endothelial growth factor (VEGF) in diabetic macular edema (DME) was tested with ranibizumab, a specific antagonist of VEGF...
  41. ncbi request reprint Trans-scleral delivery of polyamine analogs for ocular neovascularization
    Raquel Lima e Silva
    The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
    Exp Eye Res 83:1260-7. 2006
    ....
  42. ncbi request reprint Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy
    Keisuke Mori
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 43:2001-6. 2002
    ..This study was undertaken to determine whether higher levels of endogenously produced PDGF-A in the retinas of mice result in retinal detachment...
  43. ncbi request reprint VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier
    Yoshitsugu Saishin
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland, USA
    J Cell Physiol 195:241-8. 2003
    ....
  44. ncbi request reprint Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage
    Godwin Okoye
    Department of Ophthalmology, Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Neurosci 23:4164-72. 2003
    ..Double transgenic mice with inducible expression of survival factors provide valuable tools for selection of survival factor candidates for gene therapy...
  45. ncbi request reprint Agents that bind annexin A2 suppress ocular neovascularization
    Raquel Lima e Silva
    Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 225:855-64. 2010
    ....
  46. ncbi request reprint The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies
    Yoshitsugu Saishin
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Invest Ophthalmol Vis Sci 44:3656-62. 2003
    ..In this study, we investigated the effect in rho/PDGF-B and rho/PDGF-AA mice of several different receptor kinase inhibitors...
  47. ncbi request reprint Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model
    Yoshitsugu Saishin
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 44:4989-93. 2003
    ..The purpose of this study was to determine whether sustained local delivery of PKC412 in a human-sized eye inhibits choroidal neovascularization (CNV)...
  48. doi request reprint Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization
    Shu Kachi
    Department of Ophthalmology and Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Gene Ther 20:31-9. 2009
    ..These data support proceeding toward clinical studies with EIAV-based gene therapy for choroidal NV, using the VMD2 promoter to selectively drive expression of a combination of endostatin and angiostatin in RPE cells...
  49. ncbi request reprint Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies
    Hideo Akiyama
    Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 207:407-12. 2006
    ....
  50. pmc Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor
    Katsuaki Miki
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
    Ophthalmology 116:1748-54. 2009
    ....
  51. ncbi request reprint Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier
    Peter Gehlbach
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    Hum Gene Ther 14:129-41. 2003
    ..These data suggest that periocular gene transfer of sFlt-1 should be considered for treatment of choroidal neovascularization and diabetic macular edema...
  52. pmc Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib
    Kyoichi Takahashi
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Arch Ophthalmol 127:494-9. 2009
    ..To investigate pazopanib hydrochloride, a multitargeted kinase inhibitor, for treatment of choroidal neovascularization (CNV)...
  53. ncbi request reprint Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration
    Quan Dong Nguyen
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Am J Ophthalmol 145:257-266. 2008
    ..To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration...
  54. ncbi request reprint Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense system
    Katsutoshi Yokoi
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Mol Ther 15:1917-23. 2007
    ..These data suggest that ZFP TF-driven enhancement of the endogenous anti-angiogenic defense system may provide a new approach for prophylaxis and treatment of neovascular diseases of the eye...
  55. doi request reprint Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
    Quan Dong Nguyen
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 117:2146-51. 2010
    ..To determine the long-term effects of ranibizumab (RBZ) in patients with diabetic macular edema (DME)...
  56. pmc Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization
    Katsuji Kiuchi
    Department of Ophthalmology, The Johns Hopkins University of Medicine, Baltimore, MD 21287 9277, USA
    Invest Ophthalmol Vis Sci 49:1705-11. 2008
    ..By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovascularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV)...
  57. ncbi request reprint The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization
    Raquel Lima e Silva
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
    FASEB J 21:3219-30. 2007
    ..They provide new targets for therapeutic intervention that may help to bolster and supplement effects obtained with VEGF antagonists...
  58. pmc Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment
    Kyoko Ohno-Matsui
    Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287 9277, USA
    Am J Pathol 160:711-9. 2002
    ..Mice with inducible expression of VEGF in the retina provide a valuable new model of ocular neovascularization...
  59. ncbi request reprint Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive
    Yuji Oshima
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    FASEB J 19:963-5. 2005
    ....
  60. doi request reprint A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration
    Quan Dong Nguyen
    Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 116:2141-8.e1. 2009
    ....
  61. ncbi request reprint Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye
    Yoshitsugu Saishin
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Hum Gene Ther 16:473-8. 2005
    ..These data suggest that periocular gene transfer may be feasible for treatment of human choroidal diseases...
  62. ncbi request reprint Topical nepafenac inhibits ocular neovascularization
    Kyoichi Takahashi
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287 9277, USA
    Invest Ophthalmol Vis Sci 44:409-15. 2003
    ..In this study, we tested the effect of topical nepafenac in three murine models of ocular neovascularization (NV)...
  63. pmc Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization
    Tsunehiko Yoshida
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    FASEB J 24:1759-67. 2010
    ..It may also be useful for treatment of neovascular diseases in other tissues...
  64. ncbi request reprint Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells
    Akiko Miki
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 224:262-72. 2010
    ....
  65. pmc Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization
    Jikui Shen
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, Maryland 21287 9277, USA
    Mol Med 10:12-8. 2004
    ..These data suggest that Npn2 facilitates VEGF-induced retinal NV and may constitute a useful target for therapeutic intervention in ocular diseases complicated by NV...
  66. ncbi request reprint A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration
    Quan Dong Nguyen
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland MD 21287 9277, USA
    Ophthalmology 113:1522.e1-1522.e14. 2006
    ....
  67. ncbi request reprint Blockade of nitric-oxide synthase reduces choroidal neovascularization
    Akira Ando
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Mol Pharmacol 62:539-44. 2002
    ..Selective inhibitors of eNOS may be needed for treatment of retinal neovascularization...
  68. ncbi request reprint Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor
    Yuji Oshima
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Cell Physiol 199:412-7. 2004
    ..The retinal neovascularization originated from both the superficial and deep capillary beds. These data suggest that Ang2 promotes sensitivity to the angiogenic effects of VEGF in retinal vessels...
  69. ncbi request reprint Supplemental oxygen improves diabetic macular edema: a pilot study
    Quan Dong Nguyen
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 45:617-24. 2004
    ..The pathogenesis of DME is poorly understood. In this study, the effect of retinal hypoxia in the development and maintenance of DME was investigated...
  70. ncbi request reprint Ocular gene transfer with self-complementary AAV vectors
    Katsutoshi Yokoi
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 48:3324-8. 2007
    ..In this study, the authors investigated the effects of intraocular injections of type 2 scAAV.GFP in mice...
  71. ncbi request reprint Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1
    Brian D Kelly
    Program in Vascular Cell Engineering, Institute for Cell Engineering, Baltimore, MD, USA
    Circ Res 93:1074-81. 2003
    ....
  72. ncbi request reprint Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier
    Yoshitsugu Saishin
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Cell Physiol 195:210-9. 2003
    ..PKC412 may be useful for treatment of post-operative and inflammatory macular edema, in which prostaglandins play a role, as well as macular edema associated with ischemic retinopathies...
  73. ncbi request reprint Suppression and regression of choroidal neovascularization by polyamine analogues
    Raquel Lima e Silva
    Department of Ophthalmology, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
    Invest Ophthalmol Vis Sci 46:3323-30. 2005
    ..This study was conducted to investigate the effect of the decamines CGC-11144 and CGC-11150 in a mouse model of choroidal neovascularization (CNV)...
  74. ncbi request reprint Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis
    Raquel Lima e Silva
    The Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 208:161-6. 2006
    ....
  75. ncbi request reprint Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization
    Yuji Oshima
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 201:393-400. 2004
    ..These data also suggest that the effects of angiogenic proteins may vary among vascular beds, even those that are closely related, and, therefore, generalizations should be avoided...
  76. ncbi request reprint A method for analysis of gene expression in isolated mouse photoreceptor and Müller cells
    Karl J Wahlin
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9257, USA
    Mol Vis 10:366-75. 2004
    ..The purpose of this study was to develop methods to assess gene expression in single retinal cells...
  77. ncbi request reprint Sustained transduction of ocular cells with a bovine immunodeficiency viral vector
    Kyoichi Takahashi
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Gene Ther 13:1305-16. 2002
    ..There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells...
  78. ncbi request reprint Angiopoietin-2 plays an important role in retinal angiogenesis
    Sean F Hackett
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland 21287 9277, USA
    J Cell Physiol 192:182-7. 2002
    ..The data also suggest that infants with PFV should be examined for genetic modifications that would be expected to cause perturbations in Tie2 signaling...
  79. ncbi request reprint Mouse model of post-surgical breakdown of the blood-retinal barrier
    Hansheng Liu
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9289, USA
    Curr Eye Res 28:421-6. 2004
    ..Post-surgical macular edema is an important clinical problem resulting from breakdown of the blood-retinal barrier (BRB) after surgery. This study was designed to develop a mouse model of post-surgical BRB breakdown...
  80. ncbi request reprint Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization
    Hiroyuki Nambu
    The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland, USA
    J Cell Physiol 204:227-35. 2005
    ..These data suggest that increased expression of Ang1 may be a good strategy for prophylaxis of retinal NV, but is unlikely to be effective as monotherapy of established NV...
  81. ncbi request reprint Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization
    Jikui Shen
    The Departments of Ophthalmology and Neuroscience The Johns Hopkins University School of Medicine Baltimore, Maryland 21287 9277, USA
    FASEB J 20:723-5. 2006
    ..These data support the hypothesis that vasohibin acts as a negative feedback regulator of neovascularization in the retina and suggest that suppression of VEGF receptor 2 may play some role in mediating its activity...
  82. ncbi request reprint Studies on retinal and retinal pigment epithelial gene expression
    Itay Chowers
    Guerrieri Center for Genetic Engineering and Molecular Ophthalmology, Wilmer Eye Institute, USA
    Novartis Found Symp 255:131-45; discussion 145-6, 177-8. 2004
    ..We will also discuss technical issues that make expression studies of the RPE particularly challenging, and share our experience in methodological approaches to overcome these challenges...
  83. ncbi request reprint Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes
    Lucia Sobrin
    Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
    Ophthalmology 119:1874-85. 2012
    ....
  84. ncbi request reprint VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family
    Noriko Esumi
    The Guerrieri Center for Genetic Engineering and Molecular Ophthalmology, The Wilmer Eye Institute, The Departments of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9289, USA
    J Biol Chem 282:1838-50. 2007
    ..Taken together, we suggest that VMD2 is regulated by the MITF-TFE family through two E-boxes, with E-box 1 required for a direct interaction of MITF-TFE factors and E-box 2 for binding of the as yet unidentified factor(s)...
  85. pmc Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels
    Shinji Ueno
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Cell Physiol 217:13-22. 2008
    ..These data indicate that constant blockade of VEGF for up to 7 months has no identifiable deleterious effects on the retina or choroid and support the use of VEGF antagonists in the treatment of retinal diseases...
  86. ncbi request reprint Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface
    Nicola G Ghazi
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Am J Ophthalmol 144:747-754. 2007
    ..To assess the optical coherence tomography (OCT) characteristics of eyes with persistent clinically significant diabetic macular edema (PDME) after focal laser treatment, with emphasis on the vitreomacular interface (VMI) characteristics...
  87. ncbi request reprint Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization
    Hiroyuki Nambu
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Invest Ophthalmol Vis Sci 44:3650-5. 2003
    ..In this study the effect of a CA-4 prodrug, combretastatin A-4-phosphate (CA-4-P), was tested in two models of ocular neovascularization...
  88. ncbi request reprint In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels
    Jikui Shen
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Invest Ophthalmol Vis Sci 48:4335-41. 2007
    ..The purpose of this study was to identify ways to improve qualitative and quantitative assessments of retinal vessels and neovascularization (NV)...
  89. ncbi request reprint RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF
    Hisashi Ida
    Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan
    Invest Ophthalmol Vis Sci 44:5430-7. 2003
    ..In this study, the long-term course of NV and the behavior of the RPE in rhodopsin/VEGF transgenic mice, in which there is a sustained angiogenic stimulus, was investigated...
  90. pmc The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction
    Diana V Do
    Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Trans Am Ophthalmol Soc 104:161-6. 2006
    ....
  91. pmc TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage
    Stanley A Vinores
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee 825, 600 N Wolfe Street Baltimore, Maryland 21287 9289, United States
    J Neuroimmunol 182:73-9. 2007
    ..Ischemia-induced retinal neovascularization, which has previously been shown to require VEGF, does not require TNF-alpha and is unaffected by attenuation of leukostasis...
  92. ncbi request reprint Protein transport to choroid and retina following periocular injection: theoretical and experimental study
    Feilim Mac Gabhann
    Department of Biomedical Engineering, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 720 Rutland Ave, 613 Traylor, Baltimore, MD 21205, USA
    Ann Biomed Eng 35:615-30. 2007
    ..This is the first model of ocular drug delivery to explicitly account for transport properties of each eye layer...
  93. ncbi request reprint Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis
    Elia J Duh
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Am J Ophthalmol 137:668-74. 2004
    ..In this study, we sought to measure the levels of PEDF and vascular endothelial growth factor (VEGF) in the vitreous of patients with and without ocular neovascular disorders...
  94. ncbi request reprint Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization
    Yuji Oshima
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland 21287, USA
    J Cell Physiol 199:399-411. 2004
    ..This provides a model for anterior segment neovascularization, which unlike previous models is relatively inexpensive and is not plagued by spontaneous regression, and therefore, may be useful for identification of new treatments...
  95. pmc An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization
    Bing Xie
    Department of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    FASEB J 22:2775-83. 2008
    ..Perturbation of the loop by elimination of ADAM15 suppresses ocular neovascularization in 3 different model systems, and thus ADAM15 provides a new therapeutic target for diseases complicated by neovascularization...

Research Grants29

  1. FUNCTIONS OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 1999
    ..The third aim is to test the hypothesis that FGF receptor function is required for photoreceptor development and for their survival. ..
  2. Targeting survival factors for ocular neovascularization
    Peter Campochiaro; Fiscal Year: 2009
    ....
  3. Oxidative damage and cone cell death in RP
    Peter Campochiaro; Fiscal Year: 2009
    ..In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60. ..
  4. FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 2004
    ..This will provide important new information that is needed for the development of new treatments for these disease processes. ..
  5. Molecular Signals Involved in Ocular Neovascularization
    Peter Campochiaro; Fiscal Year: 2004
    ..5) Increased expression of Ang2 in the retina causes regression of neovascularization, while coexpression of Ang2 and VEGF promotes neovascularization. ..
  6. Molecular Signals Involved in Ocular Neovascularization
    Peter Campochiaro; Fiscal Year: 2005
    ..5) Increased expression of Ang2 in the retina causes regression of neovascularization, while coexpression of Ang2 and VEGF promotes neovascularization. ..
  7. Oxidative damage and cone cell death in RP
    Peter Campochiaro; Fiscal Year: 2007
    ..In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60. ..
  8. Targeting survival factors for ocular neovascularization
    Peter Campochiaro; Fiscal Year: 2007
    ....
  9. Oxidative damage and cone cell death in RP
    Peter Campochiaro; Fiscal Year: 2009
    ..In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60. ..
  10. Oxidative damage and cone cell death in RP
    Peter A Campochiaro; Fiscal Year: 2010
    ..In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60. ..
  11. Targeting survival factors for ocular neovascularization
    Peter A Campochiaro; Fiscal Year: 2010
    ....
  12. Targeting survival factors for ocular neovascularization
    Peter Campochiaro; Fiscal Year: 2009
    ....
  13. FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 2003
    ..This will provide important new information that is needed for the development of new treatments for these disease processes. ..
  14. Molecular Signals Involved in Ocular Neovascularization
    Peter Campochiaro; Fiscal Year: 2003
    ..5) Increased expression of Ang2 in the retina causes regression of neovascularization, while coexpression of Ang2 and VEGF promotes neovascularization. ..
  15. FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 2002
    ..This will provide important new information that is needed for the development of new treatments for these disease processes. ..
  16. RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
    Peter Campochiaro; Fiscal Year: 1999
    ..These studies could provide new insights into mechanisms by which retinal neovascularization occurs and identify new targets for therapeutic intervention. ..
  17. PATHOGENIC MECHANISMS IN PROLIFERATIVE VITREORETINOPATHY
    Peter Campochiaro; Fiscal Year: 1991
    ..In this manner, we hop to gain a more detailed picture of the pathogenic mechanisms involved in PVR so that strategies to prevent and interrupt them can be designed...
  18. PATHOGENIC MECHANISMS IN PROLIFERATIVE VITREORETINOPATHY
    Peter Campochiaro; Fiscal Year: 1992
    ..In this manner, we hop to gain a more detailed picture of the pathogenic mechanisms involved in PVR so that strategies to prevent and interrupt them can be designed...
  19. PATHOGENIC MECHANISMS IN PROLIFERATIVE VITREORETINOPATHY
    Peter Campochiaro; Fiscal Year: 1993
    ..In this manner, we hop to gain a more detailed picture of the pathogenic mechanisms involved in PVR so that strategies to prevent and interrupt them can be designed...
  20. RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
    Peter Campochiaro; Fiscal Year: 2000
    ..These studies could provide new insights into mechanisms by which retinal neovascularization occurs and identify new targets for therapeutic intervention. ..
  21. FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPE
    Peter Campochiaro; Fiscal Year: 2001
    ..This will provide important new information that is needed for the development of new treatments for these disease processes. ..
  22. RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
    Peter Campochiaro; Fiscal Year: 2001
    ..These studies could provide new insights into mechanisms by which retinal neovascularization occurs and identify new targets for therapeutic intervention. ..
  23. Molecular Signals Involved in Ocular Neovascularization
    Peter Campochiaro; Fiscal Year: 2002
    ..5) Increased expression of Ang2 in the retina causes regression of neovascularization, while coexpression of Ang2 and VEGF promotes neovascularization. ..